Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines

Chest

Volumn 143, Issue 5 SUPPL, 2013, Pages

  Ost, David E ^a   Yeung, Sai Ching Jim ^a   Tanoue, Lynn T ^b   Gould, Michael K ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b YALE UNIVERSITY   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIBODY; ANTIFUNGAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHROMOGRANIN A; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DEMECLOCYCLINE; DEXAMETHASONE; ELECTROLYTE; ETOMIDATE; FUROSEMIDE; GLUCOCORTICOID; HEMOGLOBIN; HU ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; LITHIUM SALT; METHYLPREDNISOLONE; METYRAPONE; MIFEPRISTONE; MITOTANE; SODIUM; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; YO ANTIBODY;

ADRENAL METASTASIS; ANTIHU SYNDROME; ANTIRI SYNDROME; ANTIYO SYNDROME; ARTICLE; ASYMPTOMATIC DISEASE; AUTOIMMUNE AUTONOMIC GANGLIONOPATHY; BONE PAIN; CALCIUM BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOID SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COCHRANE LIBRARY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CUSHING SYNDROME; DERMATOMYOSITIS; DYSPNEA; EATON LAMBERT SYNDROME; ELECTROLYTE BLOOD LEVEL; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HORNER SYNDROME; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; HYPERCORTISOLISM; HYPONATREMIA; IMMUNOPATHOLOGY; INAPPROPRIATE VASOPRESSIN SECRETION; INOPERABLE CANCER; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG CANCER; LUNG FUNCTION TEST; LUNG METASTASIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDICAL HISTORY; MEDICAL SPECIALIST; MEDLINE; MYOKYMIA; ORAL REHYDRATION THERAPY; PANCOAST TUMOR; PARANEOPLASTIC SYNDROME; PATIENT CARE; PATIENT SAFETY; PHYSICAL EXAMINATION; PLASMAPHERESIS; PNEUMOCYSTOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT LARYNGEAL NERVE PALSY; SODIUM BLOOD LEVEL; TEAMWORK; THORAX PAIN; THORAX RADIOGRAPHY; TUMOR BIOPSY; VENOUS THROMBOEMBOLISM;

EID: 84877674581     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2352     Document Type: Article

References (181)

1. Lewis SZ, Diekemper R, Addrizzo-Harris DJ. Methodology for development of guidelines for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): 41S-50S.
2. Andersen H, Prakash U. Diagnosis of symptomatic lung cancer. Semin Respir Med. 1982; 3 (3): 165-175.
3. Grippi MA. Clinical aspects of lung cancer. Semin Roentgenol. 1990; 25 (1): 12-24.
4. Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest. 1974; 65 (3): 299-306.
5. Cromartie RS III, Parker EF, May JE, Metcalf JS, Bartles DM. Carcinoma of the lung: a clinical review. Ann Thorac Surg. 1980; 30 (1): 30-35.
6. Karsell PR, McDougall JC. Diagnostic tests for lung cancer. Mayo Clin Proc. 1993; 68 (3): 288-296.
7. The American Thoracic Society, The European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997; 156 (1): 320-332.
8. Koyi H, Hillerdal G, Brandén E. Patient's and doctors' delays in the diagnosis of chest tumors. Lung Cancer. 2002; 35 (1): 53-57.
9. Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Respir J. 2004; 24 (6): 898-904.
10. Carbone P, Frost J, Feinstein A. Lung cancer: perspectives and prospects. Ann Intern Med. 1970; 73 : 1002-1024.
11. Spiro SG, Gould MK, Colice GL; American College of Chest Physicians. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007; 132(suppl 3): 149S-160S.
12. Colice GL. Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT. Chest. 1997; 111 (4): 877-884.
13. Arcasoy SM, Jett JR. Superior pulmonary sulcus tumors and Pancoast's syndrome. N Engl J Med. 1997; 337(19): 1370-1376.
14. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007; 356 (18): 1862-1869.
15. Detterbeck FC, Postmus PE, Tanoue LT. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e191S-e210S.
16. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e166S-e190S.
17. Midthun DE, Swensen SJ, Jett JR, Hartman TE. Evaluation of nodules detected by screening for lung cancer with low dose spiral computed tomography. Lung Cancer. 2003; 41 (suppl 2): S40.
18. Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997; 157 (8): 849-855.
19. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143 (5)(suppl): e93S-e120S.
20. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365 (5): 395-409.
21. Quinn D, Gianlupi A, Broste S. The changing radiographic presentation of bronchogenic carcinoma with reference to cell types. Chest. 1996; 110 (6): 1474-1479.
22. Byrd RB, Carr DT, Miller WE, Payne WS, Woolner LB. Radiographic abnormalities in carcinoma of the lung as related to histological cell type. Thorax. 1969; 24(5): 573-575.
23. Sider L. Radiographic manifestations of primary bronchogenic carcinoma. Radiol Clin North Am. 1990; 28(3): 583-597.
24. Theros EG. 1976 Caldwell Lecture: varying manifestation of peripheral pulmonary neoplasms: a radiologic-pathologic correlative study. AJR Am J Roentgenol. 1977; 128(6): 893-914.
25. Feinstein AR, Wells CK. A clinical-severity staging system for patients with lung cancer. Medicine (Baltimore). 1990; 69 (1): 1-33.
26. Merchut MP. Brain metastases from undiagnosed systemic neoplasms. Arch Intern Med. 1989; 149 (5): 1076-1080.
27. Feinstein AR, Wells CK. Lung cancer staging. A critical evaluation. Clin Chest Med. 1982; 3 (2): 291-305.
28. Feinstein AR. Symptomatic patterns, biologic behavior, and prognosis in cancer of the lung. Practical application of Boolean algebra and clinical taxonomy. Ann Intern Med. 1964; 61 : 27-43.
29. Feinstein AR. Symptoms as an index of biological behaviour and prognosis in human cancer. Nature. 1966; 209 (5020): 241-245.
30. Hooper RG, Tenholder MF, Underwood GH, Beechler CR, Spratling L. Computed tomographic scanning of the brain in initial staging of bronchogenic carcinoma. Chest. 1984; 85 (6): 774-776.
31. Hooper RG, Beechler CR, Johnson MC. Radioisotope scanning in the initial staging of bronchogenic carcinoma. Am Rev Respir Dis. 1978; 118 (2): 279-286.
32. Silvestri GA, Lenz JE, Harper SN, Morse RA, Colice GL. The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma. Chest. 1992; 102 (6): 1748-1751.
33. Quinn DL, Ostrow LB, Porter DK, Shelton DK Jr, Jackson DE Jr. Staging of non-small cell bronchogenic carcinoma. Relationship of the clinical evaluation to organ scans. Chest. 1986; 89 (2): 270-275.
34. Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestri G. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest. 1995; 108 (5): 1264-1271.
35. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer. A meta-analysis. Am J Respir Crit Care Med. 1995; 152 (1): 225-230.
36. Grant D, Edwards D, Goldstraw P. Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer. Thorax. 1988; 43 (11): 883-886.
37. Meador CK, Liddle GW, Island DP, et al. Cause of Cushing's syndrome in patients with tumors arising from "nonendocrine" tissue. J Clin Endocrinol Metab. 1962; 22 : 693-703.
38. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991; 325 (13): 897-905.
39. Wajchenberg BL, Mendonça B, Liberman B, Adelaide M, Pereira A, Kirschner MA. Ectopic ACTH syndrome. J Steroid Biochem Mol Biol. 1995; 53 (1-6): 139-151.
40. Howlett TA, Drury PL, Perry L, Doniach I, Rees LH, Besser GM. Diagnosis and management of ACTH-dependent Cushing's syndrome: comparison of the features in ectopic and pituitary ACTH production. Clin Endocrinol (Oxf). 1986; 24 (6): 699-713.
41. Dimopoulos MA, Fernandez JF, Samaan NA, Holoye PY, Vassilopoulou-Sellin R. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer. 1992; 69 (1): 66-71.
42. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab. 2000; 85 (1): 42-47.
43. Kato Y, Ferguson TB, Bennett DE, Burford TH. Oat cell carcinoma of the lung. A review of 138 cases. Cancer. 1969; 23 (3): 517-524.
44. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol. 1992; 10 (1): 21-27.
45. Delisle L, Boyer MJ, Warr D, et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med. 1993; 153 (6): 746-752.
46. Gewirtz G, Yalow RS. Ectopic ACTH production in carcinoma of the lung. J Clin Invest. 1974; 53 (4): 1022-1032.
47. Gropp C, Havemann K, Scheuer A. Ectopic hormones in lung cancer patients at diagnosis and during therapy. Cancer. 1980; 46 (2): 347-354.
48. Bondy PK, Gilby ED. Endocrine function in small cell undifferentiated carcinoma of the lung. Cancer. 1982; 50 (10): 2147-2153.
49. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005; 90 (8): 4955-4962.
50. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93 (5): 1526-1540.
51. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008; 93 (7): 2454-2462.
52. Elamin MB, Murad MH, Mullan R, et al. Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab. 2008; 93 (5): 1553-1562.
53. Guignat L, Bertherat J. The diagnosis of Cushing's syndrome: an Endocrine Society clinical practice guideline: commentary from a European perspective. Eur J Endocrinol. 2010; 163(1):9-13.
54. Small M, Lowe GD, Forbes CD, Thomson JA. Thromboembolic complications in Cushing's syndrome. Clin Endocrinol (Oxf). 1983; 19 (4): 503-511.
55. Kastelan D, Dusek T, Kraljevic I, et al. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine. 2009; 36 (1): 70-74.
56. Van Zaane B, Nur E, Squizzato A, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2009; 94 (8): 2743-2750.
57. Phan AT, Oberg K, Choi J, et al; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010; 39 (6): 784-798.
58. Katsuragi N, Shiraishi Y, Nakajima Y, Kurai M, Takahashi N, Tanaka S. Squamous cell bronchogenic carcinoma with syndrome of inappropriate secretion of antidiuretic hormone [in Japanese]. Kyobu Geka. 2004; 57 (9): 847-850.
59. Kagawa K, Fujitaka K, Isobe T, et al. Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion. Intern Med. 2001; 40 (10): 1020-1023.
60. Moses AM, Scheinman SJ. Ectopic secretion of neurohypophyseal peptides in patients with malignancy. Endocrinol Metab Clin North Am. 1991; 20 (3): 489-506.
61. Gross AJ, Steinberg SM, Reilly JG, et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res. 1993; 53 (1): 67-74.
62. Fenske W, Maier SK, Blechschmidt A, Allolio B, Störk S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. Am J Med. 2010; 123 (7): 652-657.
63. Kamoi K, Ebe T, Hasegawa A, et al. Hyponatremia in small cell lung cancer. Mechanisms not involving inappropriate ADH secretion. Cancer. 1987; 60 (5): 1089-1093.
64. Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007; 15 (12): 1341-1347.
65. Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med. 2010; 77 (10): 715-726.
66. Hiraki A, Ueoka H, Bessho A, et al. Parathyroid hormonerelated protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer. 2002; 95 (8): 1706-1713.
67. Lazaretti-Castro M, Kayath M, Jamnik S, Santoro IL, Tadokoru H, Vieira JG. Prevalence of hypercalcemia in patients with lung cancer [in Portuguese]. Rev Assoc Med Bras. 1993; 39 (2): 83-87.
68. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352 (4): 373-379.
69. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350 (16): 1655-1664.
70. Coggeshall J, Merrill W, Hande K, Des Prez R. Implications of hypercalcemia with respect to diagnosis and treatment of lung cancer. Am J Med. 1986; 80 (2): 325-328.
71. Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006; 132 (4): 410-451.
72. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M; International Society of Geriatric Oncology. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer. 2007; 43 (5): 852-858.
73. Lumachi F, Brunello A, Roma A, Basso U. Cancer-induced hypercalcemia. Anticancer Res. 2009; 29 (5): 1551-1555.
74. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008; 113 (1): 5-21.
75. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005; 40 (2): 90-97.
76. Lim E, Goldstraw P, Nicholson AG, et al. Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol. 2008; 3 (10): 1194-1201.
77. Kvols LK. Therapy of the malignant carcinoid syndrome. Endocrinol Metab Clin North Am. 1989; 18 (2): 557-568.
78. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr. 1985; 42 (4): 639-643.
79. Mashige F, Matsushima Y, Kanazawa H, et al. Acidic catecholamine metabolites and 5-hydroxyindoleacetic acid in urine: the influence of diet. Ann Clin Biochem. 1996; 33 (pt 1): 43-49.
80. Aggarwal G, Obideen K, Wehbi M. Carcinoid tumors: what should increase our suspicion? Cleve Clin J Med. 2008; 75 (12): 849-855.
81. Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J. 1995; 71 (839): 542-545.
82. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999; 86 (5): 858-865.
83. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol. 2001; 12 (suppl 2): S69-S72.
84. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2010; 257 (4): 509-517.
85. Tschernatsch M, Dierkes C, Gerriets T, et al. Paraneoplastic neurological syndromes in patients with carcinoid. Eur J Neurol. 2008; 15 (12): 1390-1394.
86. Roberts WK, Deluca IJ, Thomas A, et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8 1 T cells. J Clin Invest. 2009; 119 (7): 2042-2051.
87. de Graaf M, de Beukelaar J, Bergsma J, et al. B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol. 2008; 195 (1-2): 164-170.
88. Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4 1 T-cell balance of effector CD62Llow CD4 1 and CD62L highCD25 1 CD4 1 regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res. 2008; 14(21): 6770-6779.
89. Plonquet A, Gherardi RK, Créange A, et al. Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol. 2002; 122 (1-2): 100-105.
90. Monstad SE, Knudsen A, Salvesen HB, Aarseth JH, Vedeler CA. Onconeural antibodies in sera from patients with var-ious types of tumours. Cancer Immunol Immunother. 2009; 58 (11): 1795-1800.
91. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci. 2008; 65 (20): 3168-3181.
92. Fornaro M, Raimondo S, Lee JM, Giacobini-Robecchi MG. Neuron-specific Hu proteins sub-cellular localization in primary sensory neurons. Ann Anat. 2007; 189(3): 223-228.
93. Dalmau J, Graus F, Cheung NK, et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer. 1995; 75 (1): 99-109.
94. Senties-Madrid H, Vega-Boada F. Paraneoplastic syndromes associated with anti-Hu antibodies. Isr Med Assoc J. 2001; 3 (2): 94-103.
95. Rousseau A, Benyahia B, Dalmau J, et al. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol. 2005; 71 (3): 231-236.
96. de Graaf MT, de Beukelaar JW, Haasnoot GW, et al. HLA-DQ2 1 individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol. 2010; 226 (1-2): 147-149.
97. Hammam T, McFadzean RM, Ironside JW. Anti-hu paraneoplastic syndrome presenting as bilateral sixth cranial nerve palsies. J Neuroophthalmol. 2005; 25 (2): 101-104.
98. Eggers C, Hagel C, Pfeiffer G. Anti-Hu-associated paraneoplastic sensory neuropathy with peripheral nerve demyelination and microvasculitis. J Neurol Sci. 1998; 155 (2): 178-181.
99. Espay AJ, Kumar V, Sarpel G. Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus. J Neurol Sci. 2006; 246 (1-2): 149-152.
100. Suzuki M, Kimura H, Tachibana I, et al. Improvement of anti-Hu-associated paraneoplastic sensory neuropathy after chemoradiotherapy in a small cell lung cancer patient. Intern Med. 2001; 40 (11): 1140-1143.
101. Keime-Guibert F, Graus F, Broët P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999; 53 (8): 1719-1723.
102. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000; 68 (4): 479-482.
103. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007; 21 (suppl 1): S57-S107.
104. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol. 2010; 69 (10): 997-1007.
105. Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol. 2003; 63 (2): 187-190.
106. Landtblom AM, Lindvall B, Ledin T, Berlin G. A case report of plasmapheresis treatment in a patient with paraneoplastic cerebellar degeneration and high anti-yo antibody titers. Ther Apher Dial. 2008; 12 (1): 82-85.
107. Meloni C, Iani C, Dominijanni S, et al. A case report of plasma exchange therapy in non-paraneoplastic cerebellar ataxia associated with anti-Yo antibody. Ther Apher Dial. 2004; 8 (6): 500-502.
108. Buckanovich RJ, Posner JB, Darnell RB. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron. 1993; 11 (4): 657-672.
109. Knudsen A, Monstad SE, Dørum A, et al. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother. 2006; 55 (10): 1280-1284.
110. Prommer E. Neuromuscular paraneoplastic syndromes: the Lambert-Eaton myasthenic syndrome. J Palliat Med. 2010; 13 (9): 1159-1162.
111. Vincent A. Autoimmune channelopathies: well-established and emerging immunotherapy-responsive diseases of the peripheral and central nervous systems. J Clin Immunol. 2010; 30 (suppl 1): S97-S102.
112. Voltz R, Carpentier AF, Rosenfeld MR, Posner JB, Dalmau J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve. 1999; 22 (1): 119-122.
113. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calciumchannel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995; 332 (22): 1467-1474.
114. Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry. 1991; 54 (9): 764-767.
115. Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer. 2004; 100 (4): 801-806.
116. Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. Semin Neurol. 2004; 24 (2): 149-153.
117. Payne M, Bradbury P, Lang B, et al. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol. 2010; 5 (1): 34-38.
118. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2005; (2): CD003279.
119. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain. 1993; 116 (pt 2): 453-469.
120. Vernino S. Autoimmune and paraneoplastic channelopathies. Neurotherapeutics. 2007; 4 (2): 305-314.
121. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000; 343 (12): 847-855.
122. Winston N, Vernino S. Autoimmune autonomic ganglionopathy. Front Neurol Neurosci. 2009; 26 : 85-93.
123. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292 (8): 403-407.
124. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292 (7): 344-347.
125. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010; 12 (2): R70.
126. Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci. 2009; 13 (2): 77-80.
127. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001; 357 (9250): 96-100.
128. Levine SM. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol. 2006; 18 (6): 620-624.
129. Krathen MS, Fiorentino D, Werth VP. Dermatomyositis. Curr Dir Autoimmun. 2008; 10 : 313-332.
130. Antonioli CM, Airò P. Dermatomyositis associated with lymphoproliferative disorder of NK cells and occult small cell lung carcinoma. Clin Rheumatol. 2004; 23 (3): 239-241.
131. Iorizzo LJ III, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008; 59 (1): 99-112.
132. Elovaara I, Apostolski S, van Doorn P, et al; EFNS. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008; 15 (9): 893-908.
133. Institute of Medicine (Committee on Quality of Health Care in America). Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC : National Academies Press; 2001.
134. Finlay GA, Joseph B, Rodrigues CR, Griffith J, White AC. Advanced presentation of lung cancer in Asian immigrants: a case-control study. Chest. 2002;122(6):1938-1943.
135. Quarterman RL, McMillan A, Ratcliffe MB, Block MI. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2003; 125 (1): 108-113.
136. Liu DM, Kwee SA. Demographic, treatment, and survival patterns for Native Hawaiians with lung cancer treated at a community medical center from 1995 to 2001. Pac Health Dialog. 2004;11(2):139-145.
137. Dransfield MT, Lock BJ, Garver RI, Jr. Improving the lung cancer resection rate in the US Department of Veterans Affairs Health System. Clin Lung Cancer. 2006;7(4):268-272.
138. Riedel RF, Wang X, McCormack M, et al. Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. J Thorac Oncol. 2006; 1 (7): 692-696.
139. Gould MK, Ghaus SJ, Olsson JK, Schultz EM. Timeliness of care in veterans with non-small cell lung cancer. Chest. 2008; 133 (5): 1167-1173.
140. Schultz EM, Powell AA, McMillan A, et al. Hospital characteristics associated with timeliness of care in veterans with lung cancer. Am J Respir Crit Care Med. 2009; 179 (7): 595-600.
141. Yorio JT, Xie Y, Yan J, Gerber DE. Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? J Thorac Oncol. 2009; 4 (11): 1322-1330.
142. Kernstine KH, Reckamp KL, eds. Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management. New York, NY: Demos Medical; 2011.
143. Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006; 56 (532): 863-868.
144. Strojan P, Debevec M, Kovac V. Superior sulcus tumor (SST): management at the Institute of Oncology in Ljubljana, Slovenia, 1981-1994. Lung Cancer. 1997; 17 (2-3): 249-259.
145. Johnston GM, MacGarvie VL, Elliott D, Dewar RA, MacIntyre MM, Nolan MC. Radiotherapy wait times for patients with a diagnosis of invasive cancer, 1992-2000. Clin Invest Med. 2004; 27 (3): 142-156.
146. Annakkaya AN, Arbak P, Balbay O, Bilgin C, Erbas M, Bulut I. Effect of symptom-to-treatment interval on prognosis in lung cancer. Tumori. 2007; 93 (1): 61-67.
147. Simunovic M, Thériault ME, Paszat L, et al. Using administrative databases to measure waiting times for patients undergoing major cancer surgery in Ontario, 1993-2000. Can J Surg. 2005; 48 (2): 137-142.
148. Kesson E, Bucknall CE, McAlpine LG, et al. Lung cancer-management and outcome in Glasgow, 1991-92. Br J Cancer. 1998; 78 (10): 1391-1395.
149. Devbhandari MP, Soon SY, Quennell P, et al. UK waiting time targets in lung cancer treatment: are they achievable? Results of a prospective tracking study. J Cardiothorac Surg. 2007; 2 : 5.
150. Ringbaek T, Borgeskov S, Lange P, Viskum K. Diagnostic and therapeutic process and prognosis in suspected lung cancer. Scand Cardiovasc J. 1999; 33 (6): 337-343.
151. Bardell T, Belliveau P, Kong W, Mackillop WJ. Waiting times for cancer surgery in Ontario: 1984-2000. Clin Oncol (R Coll Radiol). 2006; 18 (5): 401-409.
152. Simunovic M, Rempel E, Thériault ME, et al. Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg. 2006; 49 (4): 251-258.
153. Berthelet E, Truong PT, Lesperance M, et al. Examining time intervals between diagnosis and treatment in the management of patients with limited stage small cell lung cancer. Am J Clin Oncol. 2006; 29 (1): 21-26.
154. Comber H, Cronin DP, Deady S, Lorcain PO, Riordan P. Delays in treatment in the cancer services: impact on cancer stage and survival. Ir Med J. 2005; 98 (8): 238-239.
155. Myrdal G, Lambe M, Hillerdal G, Lamberg K, Agustsson T, Ståhle E. Effect of delays on prognosis in patients with nonsmall cell lung cancer. Thorax. 2004; 59 (1): 45-49.
156. Aragoneses FG, Moreno N, Leon P, Fontan EG, Folque E; Bronchogenic Carcinoma Cooperative Group of the Spanish Society of Pneumology and Thoracic Surgery (GCCB-S). Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer. 2002; 36 (1): 59-63.
157. Pita-Fernández S, Montero-Martinez C, Pértega-Diaz S, Verea-Hernando H. Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. J Clin Epidemiol. 2003; 56 (9): 820-825.
158. Kashiwabara K, Koshi S, Itonaga K, Nakahara O, Tanaka M, Toyonaga M. Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. Lung Cancer. 2003; 40 (1): 67-72.
159. Kanashiki M, Satoh H, Ishikawa H, Yamashita YT, Ohtsuka M, Sekizawa K. Time from finding abnormality on massscreening to final diagnosis of lung cancer. Oncol Rep. 2003; 10 (3): 649-652.
160. O'Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol (R Coll Radiol). 2000; 12 (3): 141-144.
161. Ost DE, Gould MK. Decision making in patients with pulmonary nodules. Am J Respir Crit Care Med. 2012; 185(4): 363-372.
162. Aoki T, Nakata H, Watanabe H, et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol. 2000; 174 (3): 763-768.
163. Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol. 2000; 73 (876): 1252-1259.
164. Takashima S, Sone S, Li F, et al. Small solitary pulmonary nodules (, or 5 1 cm) detected at population-based CT screening for lung cancer: Reliable high-resolution CT features of benign lesions. AJR Am J Roentgenol. 2003; 180 (4): 955-964.
165. Yankelevitz DF, Henschke CI. Does 2-year stability imply that pulmonary nodules are benign? AJR Am J Roentgenol. 1997; 168 (2): 325-328.
166. Yankelevitz DF, Reeves AP, Kostis WJ, Zhao B, Henschke CI. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology. 2000; 217 (1): 251-256.
167. Leary A, Corrigan P. Redesign of thoracic surgical services within a cancer network-using an oncology focus to inform change. Eur J Oncol Nurs. 2005; 9(1):74-78.
168. Davison AG, Eraut CD, Haque AS, et al. Telemedicine for multidisciplinary lung cancer meetings. J Telemed Telecare. 2004; 10 (3): 140-143.
169. Laroche C, Wells F, Coulden R, et al. Improving surgical resection rate in lung cancer. Thorax. 1998; 53 (6): 445-449.
170. Murray PV, O'Brien ME, Sayer R, et al. The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. Lung Cancer. 2003; 42 (3): 283-290.
171. Lewis NR, Le Jeune I, Baldwin DR. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway. Br J Cancer. 2005; 93 (8): 905-908.
172. The Lung Cancer Working Party of the British Thoracic Society Standards of Care Committee. BTS recommendations to respiratory physicians for organising the care of patients with lung cancer. Thorax. 1998; 53 (suppl 1): S1-S8.
173. Reifel J. Lung Cancer. In: Asch S, Kerr E, Hamilton E, eds. Quality of Care for Oncologic Conditions and HIV: A Review of the Literature and Quality Indicators. RAND Corporation; 2000 : 133-172.
174. Ost DE, Gould MK. Decision making in the patient with pulmonary nodules. Am J Respir Crit Care Med. 2012; 185 (4): 363-372.
175. Crinò L, Weder W, van Meerbeeck J, Felip E; ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v103-v115.
176. Alberts WM, Bepler G, Hazelton T, Ruckdeschel JC, Williams JH Jr; American College of Chest Physicians. Lung cancer. Practice organization. Chest. 2003; 123(suppl 1): 332S-337S.
177. British Thoracic Society; Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001; 56 (2): 89-108.
178. Dillman RO, Chico SD. Cancer patient survival improvement is correlated with the opening of a community cancer center: comparisons with intramural and extramural benchmarks. J Oncol Pract. 2005; 1 (3): 84-92.
179. Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the
180. Martin-Ucar AE, Waller DA, Atkins JL, Swinson D, O'Byrne KJ, Peake MD. The beneficial effects of specialist thoracic surgery on the resection rate for non-small-cell lung cancer. Lung Cancer. 2004; 46 (2): 227-232.
181. Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM. Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer. 2008; 60 (1): 14-21.